ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Balancing Optimism & Skepticism in CAR T for SLE

  |  

References

  1. Nordmann-Gomes A, Khalili L, Tang W, et al. CAR T-cell therapy in SLE: A systematic review. Semin Arthritis Rheum. 2025 Oct;74:152786. 
  2. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease—A case series with follow-up. N Engl J Med. 2024 Feb 22;390(8):687–700. 
  3. Hagen M, Müller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025 Jun;7(6):e424–e433. 
  4. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009 Apr 15;61(4):482–487.
  5. Garantziotis P, Beretta L, Lindblom J, et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann Rheum Dis. 2025 Jul 22:S0003–S4967(25)04187-1.

Related Articles
    Editor's Pick

    B Cell-Depleting Therapy in SLE

    “SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”